FMP
Enter
API Tools
Extras
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
Valuation Date:
Jun 28, 2021 4:00 AM
Share Price on Valuation Date
$1.06
Stock Beta
0.476276
Shares Outstanding
10517100
